Hi everyone welcome to the A6 and Z podcast network I'm Sonel and this is a

special 2X episode of 16 minutes which we're also running on the main A6 and

podcast as part of our ongoing such coverage and it's all about the recent news, science, technology, problem, and

and innovations behind malaria vaccines. While the discussion includes

contrast and comparisons to COVID

vaccines briefly and also plays out against a broader backdrop of the

massive recent surge of cases in India and South Asia as well as new waves in Brazil, Turkey, France, Argentina, and elsewhere,

the big news that also came out this past week is that a new candidate malaria vaccine

is the first to achieve the World Health Organization's goal of 75%

efficacy according to the announcement from Oxford University.

Just to give a sense of how big and buzzy this news has been,

some of the keywords that have been quoted by experts in many of the releases and articles

have included phrases from unprecedented, groundbreaking work, very exciting, to high expectations, highly effective,

and a hugely significant extra weapon.

So as is the premise of 16 minutes, which if you're not already

subscribed to, be sure to find and follow in your podcast app. We dig beyond the

headlines for what's hype, what's real, as well as where we are on the long arc of innovation.

Our expert guests for this episode are Rajiv Vincaya, president of the Global Vaccine

Business Unit at Decatur Pharmaceuticals, where he leads full-stack development of vaccines for tropical diseases like

Dengue, Norovirus, and Zika.

He's also been trained as a medical doctor and served as director of vaccine delivery at the

Gates Foundation and was previously in the White House in Bio Defense. of vaccine

...